clinical trial · NCT07710430
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
LG Chem·phase4·not yet recruiting·n = 43
Central Precocious PubertyLeuprorelin
brief summary
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty
started
Aug 1, 2026
primary completion
Aug 30, 2029
completion
Apr 30, 2030
last updated
Jul 21, 2026
official title
A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children With Central Precocious Puberty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol